A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

Active:	Yes
Cancer Type:	Anal Cancer Bladder Cancer Cervical Cancer Esophogeal Cancer Lung Cancer Penile Cancer Urethral Cancer	NCT ID:	NCT07217171
Trial Phases:	Phase I	Protocol IDs:	EIU-104101 (primary) Drug: EVOLVE104
Eligibility:	18 Years and older (Adult, Older Adult ), Male and Female	Study Type:	Treatment
Study Sponsor:	EvolveImmune United, Inc
NCI Full Details:	https://clinicaltrials.gov/study/NCT07217171

Summary

The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with advanced or metastatic cancer who meet all eligibility criteria may be eligible to participate in the study.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.